Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.3 to v3.5.4, indicating a small update to the page metadata. This reflects an editorial change to the ClinicalTrials.gov record rather than any substantive study information.
    Difference
    0.0%
    Check dated 2026-05-15T04:21:01.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page now displays a new revision label: Revision: v3.5.3, replacing v3.5.2. This signals an update to the page version, with no evident public content changes.
    Difference
    0.0%
    Check dated 2026-04-30T18:50:35.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-16T11:16:47.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page. The change does not modify study data or user-facing functionality.
    Difference
    0.0%
    Check dated 2026-03-18T19:22:03.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Site version updated from v3.4.2 to v3.4.3. No observable changes to the study content or user-visible features.
    Difference
    0.0%
    Check dated 2026-03-11T16:55:19.000Z thumbnail image
  9. Check
    108 days ago
    Change Detected
    Summary
    A new site revision tag (Revision: v3.4.2) is added, and an older Revision: v3.4.1 tag along with a government funding lapse notice has been removed. These changes are cosmetic and do not affect trial details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T10:59:27.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.